[
	{
		"clinicalStudy": {
			"studyId": "1",
			"briefStudyTitle": "",
			"studyTitle": "",
			"studyType": "EXPANDED_ACCESS",
			"interventationModel": "Parallel Assignment",
			"studyIdentifier": [
				{
					"studyIdentifierId": "",
					"items": "",
					"identifierType": {
						"identifierTypeId": 1,
						"code": "NCT03991988",
						"name": "ClinicalTrials.gov"

					}
				}
			],

			"studyPhase": "PHASE_1_TRAIL",

			"studyProtocol": {
				"amendments": [
					{
						"date": "",
						"version": "V1"
					}
				],
				"protocolId": "C400-1001",
				"briefTitle": "",
				"officialTitle": "",
				"publicTitle": "",
				"version": "Draft/Final",
				"sections": [ "", "" ]
			},

			"investigationalIntervention": [
				{
					"investigationalInterventionId": "",
					"id": "DRUG",
					"description": "",
					"coding": [
						{
							"code": "",
							"codeSystem": "",
							"codeSystemVersion": "",
							"decode": ""
						}
					]
				}
			],

			"studyIndication": {
				"studyIndicationId": 1,
				"coding": [
					{
						"code": "",
						"codeSystem": "",
						"codeSystemVersion": "",
						"decode": ""
					}
				],
				"description": "Influenza",
				"id": 5
			},

			"studyObjective": [
				{
					"studyobjectiveId": 1,
					"ObjectiveLevel": "PRIMARY",
					"Objective": [
						{
							"description": "A surveillance study To assess the safety of AZD6738 and Durvalumab combination or AZD6738 and Olaparib combination in biliary tract cancer patients",
							"endpoints": [
								{
									"OutcomeLevel": "PRIMARY",
									"endpoint": [
										{
											"description": "",
											"purpose": "SAFETY"
										}
									]
								}
							]
						}
					]
				}
			],

			"studyEndpoint": [
				{
					"studyEndPointId": "1",
					"position": "",
					"items": [ "" ]
				}
			],

			"studyTargetPopulation": [
				{
					"Id": "",
					"Description": ""
				}
			],

			"trialIntentType": [ "TREATMENT" ],
			"trialType": [ "EFFICACY" ],

			"StudyEstimands": {
				"Level": "primary",
				"Estimands": [
					{
						"PopulationSummaryMeasures": [],
						"TreatmentCondition": [],
						"studyTargetPopulations": [

							{
								"targetPopulationId": 1,
								"studytargetPopulationDescription": "healthy volunteers of age between 18 and 65"
							}
						]

					}
				]
			},
			"InterCurrentEvents": [],

			"StudyDesign": [
				{
					"Indication": "",
					"StudyType": "",
					"TrialType": "",
					"TrialIntentType": "",
					"InterventionModel": "",
					"InvestigationalIntervention": [
						{
							"Id": "",
							"Description": "",
							"Coding": [
								{
									"Catalogue": "",
									"CatalogueVersion": "",
									"Code": "",
									"Decode": ""
								}
							]
						}
					],
					"Design": {
						"StudyCells": {
							"StudyElement": {
								"Name": "",
								"Type": ""
							},
							"StudyArms": {
								"Type": "",
								"Origin": {
									"OutsideThisClinicalStudy": "",
									"WithThisClinicalStudy": ""
								}
							},
							"StudyEpochs": {
								"Name": "",
								"Type": "",
								"ClinicalEncounters": ""
							}
						}
					}
				}
			]
		}
	},
	{		
		"clinicalStudy": {
			"studyId": "2",
			"studyTitle": "Vaccine Ig Levels in Nasal Mucosa as Measured by Nasal Epithelial Lining Fluid",
			"studyType": "EXPANDED_ACCESS",
			"interventationModel": "Parallel Assignment",
			"investigationalIntervention": [
				{
					"investigationalInterventionId": "1",
					"id": "DRUG",
					"description": "AZD6738",
					"coding": [
						{
							"code": "",
							"codeSystem": "",
							"codeSystemVersion": "",
							"decode": ""
						}
					]
				}
			],
			"studyIdentifier": [
				{
					"id": "1",
					"idType": {
						"code": "NCT04298021",
						"name": "ClinicalTrials"
					}
				}
			],
			"studyObjective": [
				{
					"studyobjectiveId": 1,
					"ObjectiveLevel": "PRIMARY",
					"Objective": [
						{
							"description": "A surveillance study To assess the safety of AZD6738 and Durvalumab combination or AZD6738 and Olaparib combination in biliary tract cancer patients",
							"endpoints": [
								{
									"OutcomeLevel": "PRIMARY",
									"endpoint": [
										{
											"description": "",
											"purpose": "SAFETY"
										}
									]
								}
							]
						}
					]
				}
			],
			"studyPhase": "PHASE_1_TRAIL",
			"studyProtocol": {
				"amendments": [
					{
						"amendmentdate": "",
						"version": "V1"
					}
				],
				"briefTitle": "Umbrella Study of Targeting Agents in Advanced Biliary Tract Cancer",
				"officialTitle": "",
				"protocolId": "C400-1001",
				"publicTitle": "",
				"version": "Draft/Final",
				"sections": [
					"",
					""
				]
			},
			"studyTargetIndication": {
				"studyIndicationId": 1,
				"coding": [
					{
						"code": "",
						"codeSystem": "",
						"codeSystemVersion": "",
						"decode": ""
					}
				],
				"description": "Bile duct cancer",
				"id": 5
			},
			"studyTargetPopulation": [
				{
					"Id": "1",
					"Description": "biliary tract cancer patients who have failed to 1st-line chemotherapy"
				}
			]
		}
	}
]